Metabolic-associated fatty liver disease, An Issue of Endocrinology and Metabolism Clinics of North America
- 1st Edition, Volume 52-3 - July 25, 2023
- Editors: Joseph M. Pappachan, Sherouk Fouda
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 4 0 7 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 4 0 8 - 6
In this issue of Endocrinology and Metabolism Clinics of North America, guest editors Drs. Sherouk Fouda and Joseph M. Pappachan bring their considerable expertise to the topic of… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote-
Contains 12 practice-oriented topics including obstructive sleep apnea and MAFLD; the interlink between MAFLD and polycystic ovary syndrome; pregnancy and MAFLD; MAFLD and gut microbiota; and more.
-
Provides in-depth clinical reviews of metabolic associated fatty liver disease, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Foreword
- Preface
- Pathobiology of Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Pathobiology of metabolic-associated fatty liver disease
- Risk factors for metabolic-associated fatty liver disease
- Dietary intake
- Sedentary lifestyle
- Viral infection and gut microbiota
- Childhood and adolescent associations
- Clinical association of metabolic-associated fatty liver disease with metabolic/nonmetabolic disorders
- Summary
- Clinics care points
- Metabolic-Associated Fatty Liver Disease in Childhood and Adolescence
- Key points
- Introduction
- Epidemiologic burden
- Cause
- Pathophysiology
- Pathology and classification
- Evaluation and diagnosis
- Management and limitations
- Evolving treatments
- Summary
- Clinics care points
- Disclosures
- Lean Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Definition of lean metabolic-associated fatty liver disease
- Prevalence
- Pathophysiologic characteristics
- Treatments
- Research
- Summary
- Clinics care points
- Disclosure
- Lipid Disorders and Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Summary
- Clinics care points
- Disclosure
- Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease
- Key points
- Introduction
- Epidemiological evidence
- Evidence for a causal relationship
- Implications for treatment of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease
- Implications for prevention of cardiovascular disease
- Areas of uncertainty/emerging concepts
- Summary
- Clinics care points
- Declaration of Interests
- Metabolic-Associated Fatty Liver Disease and Diabetes: A Double Whammy
- Key points
- Introduction
- Problem statement of metabolic-associated fatty liver disease and diabetes
- Liver pancreas cross talk
- Metabolic syndrome and metabolic-associated fatty liver disease
- Exercise-related interventions for the management of metabolic-associated fatty liver disease with diabetes
- Pharmacotherapy for the management of metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus
- The utility of other drugs (not antidiabetic agents) in the management of metabolic-associated fatty liver disease
- Bariatric surgery and intragastric procedures
- Management of metabolic-associated fatty liver disease among patients with diabetes in special situations
- Outcomes of metabolic-associated fatty liver disease in patients with diabetes as compared with those without diabetes
- Summary
- Clinics care points
- Metabolic-Associated Fatty Liver Disease and the Gut Microbiota
- Key points
- Introduction
- Summary and future directions
- Clinics care points
- Conflict of interest and financial disclosure
- Funding
- Metabolic-Associated Fatty Liver Disease and Sarcopenia
- Key points
- Introduction
- The interlink between sarcopenia and metabolic-associated fatty liver disease
- Cause-effect relationship
- Metabolic-associated fatty liver disease and sarcopenic obesity
- Screening and diagnosis (assessing muscle composition, strength, and performance in metabolic-associated fatty liver disease)
- Complications (especially when both entities coexist, including cardiovascular risk)
- Therapeutic and lifestyle interventions
- Summary
- Clinics care points
- A Bidirectional Association Between Obstructive Sleep Apnea and Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Epidemiology
- Diagnostic approach
- Obstructive sleep apnea and metabolic-associated fatty liver disease
- Pathophysiology
- Management algorithm
- Clinics care points
- Summary
- Disclosure
- Pregnancy and Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Preclinical models for maternal metabolic-associated fatty liver disease and effects on maternal outcomes during pregnancy
- Effect of metabolic-associated fatty liver disease on maternal outcomes during pregnancy: clinical evidence
- Research evidence on the effects of maternal metabolic-associated fatty liver disease on offspring outcomes
- Clinical evidence on the effect of maternal metabolic-associated fatty liver disease on progeny
- Management of metabolic-associated fatty liver disease in pregnancy
- Summary and future directions
- Clinics care points
- Disclosure
- Funding
- The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome
- Key points
- Introduction
- Pathophysiology of polycystic ovary syndrome
- The interlink between polycystic ovary syndrome and metabolic-associated fatty liver disease
- The coexistence of polycystic ovary syndrome and metabolic-associated fatty liver disease
- Diagnostic workup
- Complication profile, including cardiovascular risks
- Current management strategies and therapeutics
- Summary
- Clinics care points
- Declaration of Interests
- Management of Metabolic-Associated Fatty Liver Disease
- Key points
- Introduction
- Screening and diagnosis
- Clinical management of MAFLD
- Clinical management of advanced MAFLD
- Summary
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 52-3
- Published: July 25, 2023
- Imprint: Elsevier
- Hardback ISBN: 9780443184079
- eBook ISBN: 9780443184086
JP
Joseph M. Pappachan
Professor Pappachan M Joseph is a senior consultant Endocrinologist in the UK and honorary professor at the Manchester Metropolitan University. He is an associate editor to Frontiers in Clinical Diabetes & Healthcare, the World Journal of Diabetes, and TouchREVIEWS in Endocrinology. He is also in the editorial board member of the American Endocrine Society Journal – JCEM Case Reports, has fully edited multiple journal issues in the past, and is the lead editor to the Elsevier Textbook “Endocrine Hypertension: From Basic Science to Clinical Practice”. He has 135 scientific publications in his credit in peer reviewed journals and has several multinational research collaborations. His academic h-index is 35 with more than 4200 citations of his works to date. His research special interests include obesity, metabolic disorders including MAFLD, neuroendocrinology & parathyroid disorders.
SF